71 related articles for article (PubMed ID: 10499600)
1. A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.
Bauer KS; Figg WD; Hamilton JM; Jones EC; Premkumar A; Steinberg SM; Dyer V; Linehan WM; Pluda JM; Reed E
Clin Cancer Res; 1999 Sep; 5(9):2324-9. PubMed ID: 10499600
[TBL] [Abstract][Full Text] [Related]
2. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.
Kohn EC; Reed E; Sarosy G; Christian M; Link CJ; Cole K; Figg WD; Davis PA; Jacob J; Goldspiel B; Liotta LA
Cancer Res; 1996 Feb; 56(3):569-73. PubMed ID: 8564973
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
Hussain MM; Kotz H; Minasian L; Premkumar A; Sarosy G; Reed E; Zhai S; Steinberg SM; Raggio M; Oliver VK; Figg WD; Kohn EC
J Clin Oncol; 2003 Dec; 21(23):4356-63. PubMed ID: 14645425
[TBL] [Abstract][Full Text] [Related]
4. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.
Smith MR; Kaufman D; George D; Oh WK; Kazanis M; Manola J; Kantoff PW
Cancer; 2002 Nov; 95(9):1864-8. PubMed ID: 12404279
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Krüger EA; Gubish E; Pluda JM; Reed E
Clin Cancer Res; 2001 Jul; 7(7):1888-93. PubMed ID: 11448901
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.
Vaishampayan U; Glode M; Du W; Kraft A; Hudes G; Wright J; Hussain M
Clin Cancer Res; 2000 Nov; 6(11):4205-8. PubMed ID: 11106233
[TBL] [Abstract][Full Text] [Related]
7. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction.
Figg WD; Cole KA; Reed E; Steinberg SM; Piscitelli SC; Davis PA; Soltis MJ; Jacob J; Boudoulas S; Goldspiel B
Clin Cancer Res; 1995 Aug; 1(8):797-803. PubMed ID: 9816048
[TBL] [Abstract][Full Text] [Related]
10. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.
Trump DL; Potter DM; Muindi J; Brufsky A; Johnson CS
Cancer; 2006 May; 106(10):2136-42. PubMed ID: 16598750
[TBL] [Abstract][Full Text] [Related]
12. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Kohn EC; Reed E; Sarosy GA; Minasian L; Bauer KS; Bostick-Bruton F; Kulpa V; Fuse E; Tompkins A; Noone M; Goldspiel B; Pluda J; Figg WD; Liotta LA
Clin Cancer Res; 2001 Jun; 7(6):1600-9. PubMed ID: 11410496
[TBL] [Abstract][Full Text] [Related]
14. In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer.
Mougenot P; Bressolle F; Culine S; Solassol I; Poujol S; Pinguet F
Anticancer Res; 2006; 26(3B):2197-203. PubMed ID: 16821586
[TBL] [Abstract][Full Text] [Related]
15. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
[TBL] [Abstract][Full Text] [Related]
17. [High dose fosfestrol in phase I-II trial for the treatment of hormone-resistant prostatic adenocarcinoma].
Kattan J; Droz JP; Culine S
Bull Cancer; 1993 Mar; 80(3):248-54. PubMed ID: 8173177
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
Daliani DD; Assikis V; Tu SM; Papandreou CN; Pagliaro LC; Holtkamp T; Wang X; Thall PF; Logothetis CJ
Cancer; 2003 Feb; 97(3):561-7. PubMed ID: 12548597
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
Scholz M; Jennrich R; Strum S; Brosman S; Johnson H; Lam R
J Urol; 2005 Jun; 173(6):1947-52. PubMed ID: 15879788
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC
Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
